approval
saveRYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 6mo ago
Found something off?
drug timeline · 8
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 7, 2025 · 378d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalOct 8, 2025 · 408d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 14, 2025 · 463d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalFeb 14, 2025 · 644d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 19, 2024 · 792d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024 · 823d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalMar 1, 2024 · 994d ago
- approvalRYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 4, 2022 · 1477d ago
same company · ±60 days · 6
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalAug 19, 2025
- approvaltalquetamab: TALVEY (TALQUETAMAB-TGVS) — FDA approvalAug 19, 2025
- approvalguselkumab: TREMFYA (GUSELKUMAB) — FDA approvalSep 19, 2025
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 14, 2025
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 14, 2025
- approvalguselkumab: TREMFYA (GUSELKUMAB) — FDA approvalSep 26, 2025
comments(0)
5-min edit window · permanent after that